Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
61 studies found for:    "hereditary paraganglioma-pheochromocytoma" OR "Paraganglioma"
Show Display Options
Rank Status Study
1 Terminated Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention:
2 Recruiting Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Drug: Sunitinib
3 Recruiting First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Condition: Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)
Interventions: Drug: Sunitinib;   Drug: Placebo
4 Active, not recruiting Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation
Conditions: Paragangliomas;   Pheochromocytomas
Intervention: Other: PET-CT
5 Completed
Has Results
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane (MIBG) I 131
6 Active, not recruiting A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Radiation: Ultratrace® Iobenguane I131
7 Available Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Ultratrace Iobenguane I131
8 Active, not recruiting Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: Axitinib (AG-013736)
9 Withdrawn Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Conditions: Phaeochromocytoma;   Paraganglioma
Interventions: Drug: Vandetanib;   Radiation: 131I-mIBG
10 Available 131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma
Conditions: Neuroblastoma;   Childhood Metastatic Pheochromocytoma;   Paraganglioma
Interventions: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG);   Drug: 131 I-MIBG
11 Completed ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid
Conditions: Pheochromocytoma;   Paraganglioma;   Carcinoid
Intervention: Drug: Ultratrace iobenguane I 131
12 Available Expanded Access Protocol Using 131I-MIBG Therapy for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
13 Completed Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers
Conditions: Paraganglioma;   Pheochromocytoma
Intervention: Procedure: diagnosis methods
14 Terminated
Has Results
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma
Conditions: Extra-Adrenal Paraganglioma;   Metastatic Adrenal Gland Pheochromocytoma;   Paraganglioma;   Recurrent Adrenal Gland Pheochromocytoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pazopanib Hydrochloride
15 Completed Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma;   Essential Hypertension
Interventions: Other: plasma EM66 & CgA levels assessment;   Other: usual follow up with regular EM66 & Cga levels assessment
16 Available Expanded Access Protocol Using I131-MIBG
Conditions: Neuroblastoma;   Pheochromocytoma;   Paraganglioma
Intervention: Radiation: I-131 MIBG
17 Completed A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Radiation: 131I-MIBG
18 Unknown  Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
Conditions: Pheochromocytoma;   Paraganglioma
Intervention: Drug: 131 I-Metaiodobenzylguanidine (131 I-MIBG)
19 Completed RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid
Conditions: Pheochromocytoma;   Extra-adrenal Paraganglioma;   Non-functioning Carcinoid
Intervention: Drug: RAD001
20 Active, not recruiting Dovitinib in Neuroendocrine Tumors
Conditions: Advanced Metastatic Paraganglioma;   Advanced Metastatic Pheochromocytoma;   Recurrent Paraganglioma;   Recurrent Pheochromocytoma;   Unresectable Paraganglioma;   Unresectable Pheochromocytoma
Intervention: Drug: Dovitinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.